Press Releases

Nobilon advances first vaccine into human trials - Intranasal influenza vaccine begins PHASE I Clinical Development

BOXMEER (The Netherlands), March 12, 2009 – Nobilon, the human vaccine business unit of Schering-Plough Corporation (NYSE: SGP), today announced that it has reached an important milestone with the initiation of its first-in-human clinical development program for SCH 900795, a new intranasal Live Attenuated Influenza Vaccine (LAIV) for annual seasonal use.

Press release
12 Mar 2009, pdf (30.9 Kb)

Schering-Plough announces collaboration with World Health Organization to provide access to pandemic influenza vaccine technology to developing countries

KENILWORTH, N.J. and BOXMEER, The Netherlands, Feb. 23, 2009 – Schering-Plough Corporation (NYSE: SGP) today announced a license agreement between Nobilon, Schering-Plough’s human vaccine business unit, and the World Health Organization (WHO) to provide access to pandemic influenza vaccine manufacturing technology to developing countries.

Press release
23 Feb 2009, pdf (30.2 Kb)

European expert consortium combines forces to develop a novel pandemic influenza vaccine

A consortium of experts in the field of human virus research and vaccine development have joined forces to develop a novel pandemic influenza vaccine as a potential emergency vaccination. The four-year project has been awarded a grant of €3.5 million from the European Union to help fund the research and the development of the new vaccine. The so-called FluVac project will be coordinated by Nobilon International BV which is part of Organon, the human healthcare business unit of Akzo Nobel.

Press release
26 Sep 2007, pdf (74 Kb)

Protherics licenses its CoVaccine HT adjuvant to Nobilon for influenza vaccine indications

Nobilon International B.V., part of Organon, the human health care business unit of Akzo Nobel, and Protherics PLC, the international biopharmaceutical company focused on critical care and cancer, today announced that Nobilon has licensed Protherics' CoVaccine HT^™ adjuvant for use in pandemic influenza vaccines, and seasonal influenza vaccines in elderly people.

Press release
26 Sep 2007, pdf (64 Kb)

Nobilon acquires rights to EBx™ cell lines from Vivalis for development, production and marketing of influenza vaccines

Nobilon and Vivalis announced today that Nobilon (part of Organon, the human healthcare business unit of Akzo Nobel) has acquired rights from Vivalis to its EBx cell lines (derived from avian embryonic stem cells) and related technology platform for the development, production and marketing of human influenza vaccines, including seasonal and pandemic.

Press release
30 May 2007, pdf (37 Kb)

Nobilon, BioDiem and leading U.S. scientists developing pandemic avian flu vaccine

Scientists at Akzo Nobel's Nobilon International human vaccines business working to fight the threat of a global bird flu pandemic have received a major boost following the signing of a cooperative research and development agreement with the Centers for Disease Control and Prevention (CDC) in the United States.

Press release
30 August 2006, pdf (100 Kb)

Nobilon and NVI co-developing RSV vaccine

Nobilon has signed a contract with the Netherlands Vaccine Institute (NVI) to jointly develop a vaccine against respiratory syncytial virus (RSV)

Press release
6 July 2006, pdf (61.6 Kb)

Nobilon and CoroNovative join forces in virus discovery program

Nobilon is to work together with the Dutch Erasmus Medical Center’s spin-off, CoroNovative BV, to expand and accelerate CoroNovative’s virus discovery program.

Press release
14 June 2006, pdf (63 Kb)

For other press releases see the archive